However, KRAS and BRAF mutations are prevalent in CRC, leading to the aberrant activation of the MAPK pathway and rendering approximately 60% of CRC patients unresponsive to cetuximab therapy [14]. This evidence concerns the gene BRAF and colorectal carcinoma.